Jacobson Center for Clinical & Translational Research

Main Menu


Additional Information


Contact Us

Endocrinology/Diabetes Research

Study Title:  A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes (Identifier: NCT01455896)

Study Purpose:  Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.

Principal Investigator: Lawrence Monger, M.D.

Study Coordinator:  Denise Zeller, RN for more information, please contact 419.383.6223 

Study Title:  Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus. (Identifier: NCT01144338)

Study Purpose:  This study will compare the impact of including exenatide once weekly as part of usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary cardiovascular combined endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.

Principal Investigator: Basil Akpunonu, M.D.

Study Coordinator:  Jennifer Gilmore, for more information, please contact 419.383.6761

Study Title: A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glarigine, With or Without OADs in Subjects with Type 2 Diabetes (SWITCH 2) (Identifier:  NCT02030600)

Study Purpose: This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.

Principal Investigator: Srini Hejeebu, M.D.

Study Coordinator:  Jennifer Gilmore, for more information, please contact 419.383.6761

Last Updated: 7/2/14